Saltar al contenido
Merck

A synchronized global sweep of the internal genes of modern avian influenza virus.

Nature (2014-02-18)
Michael Worobey, Guan-Zhu Han, Andrew Rambaut
RESUMEN

Zoonotic infectious diseases such as influenza continue to pose a grave threat to human health. However, the factors that mediate the emergence of RNA viruses such as influenza A virus (IAV) are still incompletely understood. Phylogenetic inference is crucial to reconstructing the origins and tracing the flow of IAV within and between hosts. Here we show that explicitly allowing IAV host lineages to have independent rates of molecular evolution is necessary for reliable phylogenetic inference of IAV and that methods that do not do so, including 'relaxed' molecular clock models, can be positively misleading. A phylogenomic analysis using a host-specific local clock model recovers extremely consistent evolutionary histories across all genomic segments and demonstrates that the equine H7N7 lineage is a sister clade to strains from birds--as well as those from humans, swine and the equine H3N8 lineage--sharing an ancestor with them in the mid to late 1800s. Moreover, major western and eastern hemisphere avian influenza lineages inferred for each gene coalesce in the late 1800s. On the basis of these phylogenies and the synchrony of these key nodes, we infer that the internal genes of avian influenza virus (AIV) underwent a global selective sweep beginning in the late 1800s, a process that continued throughout the twentieth century and up to the present. The resulting western hemispheric AIV lineage subsequently contributed most of the genomic segments to the 1918 pandemic virus and, independently, the 1963 equine H3N8 panzootic lineage. This approach provides a clear resolution of evolutionary patterns and processes in IAV, including the flow of viral genes and genomes within and between host lineages.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Neuraminidase from Clostridium perfringens (C. welchii), Suitable for manufacturing of diagnostic kits and reagents, Type V, lyophilized powder
Sigma-Aldrich
Neuraminidase from Vibrio cholerae, Type III, buffered aqueous solution, 0.2 μm filtered, 1-5 units/mg protein (Lowry, using NAN-lactose)
Sigma-Aldrich
Neuraminidase from Vibrio cholerae, Type II, buffered aqueous solution, 8-24 units/mg protein (Lowry, using NAN-lactose)
Sigma-Aldrich
Neuraminidase from Clostridium perfringens (C. welchii), Type X, lyophilized powder, ≥50 units/mg protein (using 4MU-NANA)
Sigma-Aldrich
α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, recombinant, expressed in E. coli, buffered aqueous solution
Sigma-Aldrich
α(2→3,6,8,9) Neuraminidase from Arthrobacter ureafaciens, Proteomics Grade, suitable for MALDI-TOF MS
Sigma-Aldrich
Neuraminidase from Clostridium perfringens (C. welchii), Type VI, lyophilized powder, 6-15 units/mg protein (using 4MU-NANA), 2-10 units/mg protein (mucin)
Sigma-Aldrich
Neuraminidase from Clostridium perfringens (C. welchii), Type VIII, lyophilized powder, 10-20 units/mg protein (using 4MU-NANA), 3.5-8.0 units/mg protein (mucin)
Sigma-Aldrich
α(2→3) Neuraminidase from Streptococcus pneumoniae, buffered aqueous solution
Sigma-Aldrich
α(2→3,6) Neuraminidase from Clostridium perfringens (C. welchii), recombinant, expressed in E. coli, buffered aqueous solution, ≥250 units/mg protein
Sigma-Aldrich
Neuraminidase Agarose from Clostridium perfringens (C. welchii), Type VI-A, ammonium sulfate suspension